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patient as a weighted score of the patient’s total comorbid condi-
tions. Results: Median age was 37 years (17-67). There were 43
males  35 females. Conditioning was with Thiotepa/Busulfan
(Bu)/Cytoxan (Cy), Decitabine/Bu/Cy or Bu/Cy in 18 patients,
Fludarabine (Flu)/Melphalan in 9 patients, Flu/Ara-C/Idarubicin
in 9 patients, Flu/Bu in 7 and TBI based regimen in 35 patients.
Sixty-four patients received stem cells from a sibling donor and 14
from other related or unrelated donors. Analysis was performed
comparing patients with a CCI score of 0-2 with patients who had
a score2. These groups were also compared for patients who had
age as comorbidity and for patients who did not (age  40 yrs).
Univariate analysis showed that patients with CCI score of 0-2 had
a better overall and event free survival (OS/EFS) than patients who
had CCI score 2 (Table 1). CCI score 2 was also predictive of
non-relapse mortality (NRM). Moreover, CCI score was a stron-
ger predictor of OS, EFS and NRM in patients aged 40 years.
Conclusions: These results demonstrate the relevance of a stan-
dardized comorbidity score in predicting transplant outcomes in a
relatively homogenous population. Our analysis indicates that CCI
score can segregate patients into low or high risk for NRM and is
predictive of OS and EFS in AML/MDS patients who received an
allogeneic HSCT in 1st CR.
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Introduction: Alkylating agents and irradiation have been uti-
lized as conditioning regimen for BMT in Fanconi Anemia (FA)
for many years. FA patients (pts) are particularly hypersensitive to
these agents and its toxicity is the main cause of mortality and
morbidity after transplant. In order to decrease toxicity and main-
tain engraftment we have progressively decreased the dose of
Cyclophosphamide (CY) during the past 20 years. Material and
methods: Between 11/83 and 06/03 our BMT Unit transplanted
120 FA pts. In this study we select only pts in aplastic phase,
without myelodysplastic syndrome or leukemia. The CY doses
divided in four days were: 200 mg/kg: 10 pts; 140 mg/kg: 13 pts (8
pts received ATG 90 mg/kg or lymphoglobuline or thymoglobulin
in equivalent dose); 120 mg/kg: 8 pts; 100 mg/kg: 19 pts; 80 mg/kg:
7 pts and 60 mg/kg: 23 pts. Two pts were transplanted at the Fred
Hutchinson Cancer Research Center in Seattle (80 mg/kg: 1pt and
60 mg/kg: 1pt). All donors were full compatible HLA siblings
except in the CY60 group where there were two different full
compatible donors: a grandfather and an uncle. All pts received
cyclosporine (Csa) and methotrexate (Mtx) as GVHD immunepro-
phylaxis and prophylactic antibiotics: ﬂuconazol, sulfamethox-
azole-trimethoprim and acyclovir according to common practice.
Results: See table for pts characteristics, disease duration, previous
blood transfusions, GVHD incidence and overall survival. Chimer-
ism studies: all survivors have complete blood counts recovery to
normal values except for one pt in the CY60 group who was heavily
transfused before BMT (100 transfusions). She is now outpatient
but transfusion dependant and the VNTR shows 45% of donor
cells. Another pt in the CY60 had a late rejection (donor: grand-
father) and underwent a second transplant. He is currently alive
and well with 100% of donor cells and normal hematological
counts one year after this transplant. Conclusion: Decreasing the
dose of CY to 60mg/kg has led to a better survival, less toxicity, no
transplant related mortality and low incidence of both acute and
chronic GVHD.
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National Marrow Donor Program®(NMDP) marrow collec-
tions between December 1987 and December 1999 (n  9282)
were evaluated to identify serious complications. Using data from
standardized individual follow-up forms, a panel of ﬁve physicians
reviewed 345 cases with potentially serious medical complications
(e.g. excessive pain, adverse acute anesthesia reactions, delayed
return to normal activities or the need for additional medical
intervention) and by consensus identiﬁed 125 (1.35% of the 9282
total) serious complications. Of the 125 serious cases, proximal
cause fell into ﬁve categories: (1) mechanical injury to tissue, bone,
or nerve (n  69, or 55% of serious subset and 0.7% of total); (2)
anesthesia (n  45, or 36% of serious subset and 0.5% of total); (3)
infection (n  1, or 0.8% of serious subset and 0.01% of total); (4)
other (n  1 [grand mal seizure], or 0.8% of serious subset and
0.01% of total); and (5) serious events thought to be unrelated to
donation (n  9 [6 cases of cancer and 3 cases of herniated spinal
disk requiring major interventions], or 7% of serious subset and
0.09% of total). The 116 donors with complications directly re-
lated to donation were further characterized according to symptom
nature and duration. Sixty-seven donors (58% and 0.7% of total)
experienced prolonged recovery periods (from months to years).
Forty-nine donors (42% and 0.5% of total) experienced severe
acute reactions, mostly related to anesthesia . Univariate and mul-
tivariate analysis indicated regional anesthesia, longer duration of
collection, female gender, and older age as signiﬁcant donor char-
acteristics for risk of serious complication. In conclusion, the in-
cidence of serious complications from marrow donation is low
(1.35%) and mechanical injury was the most frequent cause of
prolonged post collection recovery. The risks of marrow collection
Table. Effect of Comorbidity Scores on Allogeneic Transplant
Outcomes in AML/MDS Patients
Outcomes for all
patients
CCI Score 0-2
(N  28)
CCI Score >2
(N  50) P value
% OS @ 2 yrs. 83 53 0.001
% EFS @ 2 yrs. 76 38 0.0004
% NRM Day100 3 14 0.02
% NRM Day360 4 26 0.02
Outcomes for pts
<40 yrs old
CCI Score 0-2
(N  24)
CCI Score >2
(N  21) P value
% OS @ 2 yrs. 91 45 0.0009
% EFS @ 2 yrs. 83 32 0.0008
% NRM Day100 0 25 0.005
% NRM Day360 0 25 0.005
Table. Decreasing Doses of Cy for FA patients
Cy 200 Cy 140 Cy 120 Cy 100 Cy 80 Cy 60
# patients 10 13 8 19 7 23
Age-yr.-M
(range) 13 (5-32) 8 (3-30) 9 (6-19) 8 (3-22) 9 (5-16) 9 (5-29)
# previous
transf.-U-M
(range) 21 (2-151) 6 (0-200) 5 (0-100) 8 (0-100) 4 (0-50) 6 (0-101)
Disease dur.-m-
M (range) 35 (1-105) 12 (4-58) 13 (7-89) 16 (4-159) 28 (21-72) 35 (1-124)
# of MTX doses
for GVHD
prophylaxis 3 (2-4) 0 (0-4) 3 (0-4) 3 (2-4) 4 (3-4) 3 (3-4)
GVHD a III-IV
% 12.5 17 0 0 28.5 4
GVHD c
extensive % 33 27 20 12.5 33 4
Survival % 30 69 50 79 57 100
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